ERBB2 and breast cancer: Globally, HER2‐positive BC accounts for approximately 20% of all BCs and is characterized by a highly aggressive disease course, more frequent relapses in the absence of effective adjuvant treatments, and poor survival in the metastatic setting (Loibl & Gianni, 2017; Ménard et al., 2000).